Payer evidence

Ensuring patient access to our medicines

Payers are responsible for either making decisions or influencing the decisions of their organisation or country to reimburse, list and pay for drugs. To make sure that we meet the needs of this important customer, this Capability focuses on continuously incorporating payer perspectives from early on and at every stage of the product lifecycle to achieve and maintain patient access to our medicines.

Read about our HealthCore collaboration

Success story

NKTR-118

NKTR-118 is an oral peripherally-acting opioid antagonist, under investigation for the treatment of opioid-induced constipation. For NKTR-118, we gathered input from a key customer group, the payer before commencing the Phase III program. We used the insight from the Payer as well as regulatory authority feedback to shape our clinical development approach and Phase III KODIAC pivotal study design.

Ruth March, Head of Personalised Healthcare & Biomarkers, AstraZeneca

Ruth March, Head of Personalised Healthcare & Biomarkers, AstraZeneca

Ruth March, Head of Personalised Healthcare & Biomarkers, AstraZeneca

<

Ruth March explains what drives her passion for working in personalised healthcare, why it is important for pharma and patients, how AstraZeneca is integrating this approach into its research and development and what benefit is already being delivered to patients in different disease areas.

Watch the video

Ruth March explains what drives her passion for working in personalised healthcare, why it is important for pharma and patients, how AstraZeneca is integrating this approach into its research and development and what benefit is already being delivered to patients in different disease areas.